Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

Journal of the National Cancer Institute

Volumn 99, Issue 3, 2007, Pages 196-205

  Hershman, Dawn ^a,b,e   Neugut, Alfred I ^a,b   Jacobson, Judith S ^b   Wang, Jian ^b   Tsai, Wei Yann ^b,c   McBride, Russell ^b   Bennett, Charles L ^d   Grann, Victor R ^a,b  

^a Columbia University ^*  (United States)

^b National Cheng Kung University ^*  (United States)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADJUVANT THERAPY; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RESIDENTIAL HOME; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; URBAN AREA; ACUTE DISEASE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER REGISTRY; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; EPIDEMIOLOGY; FOLLOW UP; INCIDENCE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MEDICARE; MYELOID LEUKEMIA; PATHOLOGY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RISK; UNITED STATES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID; LYMPHATIC METASTASIS; MEDICARE; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; ODDS RATIO; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 33847758628     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk028     Document Type: Article

References (52)

1. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor(GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992;116:177-82.
2. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Nad Compr Cane Netw 2005;3:557-71.
3. Sharma DC. Pegnlgrastim lowers side-effects of chemotherapy. Lancet Oncol 2004;5:461.
4. Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor(filgrastim) for treatment of severe chronic neutropenia. Blood 1993;81:2496-502.
5. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8.
6. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:16-70.
7. Du XL, Lairson DR, Begley CE, Fang S. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol 2005;23:8620-8.
8. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003;21:1431-9.
9. Brodsky RA, Bedi A, Jones RJ. Are growth factors leukemogenic? Leukemia 1996;10:175-7.
10. ;3 54:203-245.
11. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003;73:33-6.
12. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A, et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003;32:3 l-k
13. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101:3 862-7.
14. Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:1195-204.
15. Donadieu J, Leblanc T, Bader Meunier B, Barkaoui M, Fenneteau O, Bertrand Y, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005;90:45-53.
16. Freedman MH, Alter BP. Malignant myeloid transformation in congenital forms of neutropenia. Isr Med Assoc J 2002;4:1011-4.
17. Dale DC, Cotde TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. AmJ Hematol 2003;72:82-93.
18. Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Ruggeri EM, et al. Does the concurrent use of anthracycline and granulocyte colony- stimulating factor influence the risk of secondary leukaemia in breast cancer women? Ann Oncol 2005;16:1209-10.
19. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T, et al. Acute myelogenous leukemia in a donor after granulocyte colony- stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004;33:661-5.
20. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, et al. The Research on Adverse Drug Events and Reports(RADAR) project. JAMA 2005;293:2131-40.
21. Imashuku S, Hibi S, Bessho F, Tsuchida M, Nakahata T, Miyazaki S, et al. Detection of myelodysplastic syndrome/acute myeloid leukemia evolving from aplastic anemia in children, treated with recombinant human G-CSF. Haematologica 2003;88:ECR3 1.
22. DombretH, ChastangC, FenauxP, Reiffers J, BordessouleD, Bouabdallah R, et al. A controlled study of recombinant human granulocyte colony- stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332:1678-83.
23. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365: 1687-717.
24. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:Suppl IV3-18.
25. Manual for staging of cancer, version 6. New York(NY): Springer-Verlag; 2003.
26. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40:Suppl IV55-61.
27. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1986;40:373-83.
28. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-67.
29. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-7.
30. Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-42.
31. Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55:119-24.
32. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor(2). N Engl J Med 1992;327:99-106.
33. Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer 1990;65:2185-95.
34. Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF. N Engl J Med 1992; 326:1294-5.
35. Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study(9031). Blood 1998;91:3607-15.
36. Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710-8.
37. Growth factor allows effective dose-intensive regimen in advanced breast cancer patients. Oncology(Williston Park) 1995;9:684.
38. Webster J, Lyman GH. Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Control 1996;3:519-23.
39. Frasci G. Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome. Drugs 2002; 62:Suppl. 117-31.
40. Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Nad Cancer Inst 1977;58:1735-41.
41. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature 1976;264:542-5.
42. Praga C, BerghJ, Bliss J, BonneterreJ, Cesana B, Coombes RC, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179-91.
43. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports(RADAR) project. Br J Haematol 2006;135:642-50.
44. Bonilla MA, Gillio AP, Ruggeiro M, Kernan NA, Brochstein JA, Abboud M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989;320:1574-80.
45. Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000;96:429-36.
46. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006;107:4628-35.
47. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N EnglJ Med 2006;354:1352-61.
48. Couzin J. Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld. Science 2005;310:1755.
49. Waxman HA. The lessons of Vioxx-drug safety and sales. N EnglJ Med 2005;352:2576-8.
50. Griffin MR, Stein CM, Ray WA. Postmarketing surveillance for drug safety: surely we can do better. Clin Pharmacol Ther 2004;75:491-4.
51. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N EnglJ Med 2004;351:1089-96.
52. Ray WA, Stein CM. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 2006;354:194-201.